{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:41:33Z","timestamp":1790649693392,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1111\/jth.15662","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T15:50:54Z","timestamp":1643817054000},"page":"1115-1125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["North American Study for the Treatment of Recurrent Epistaxis with Doxycycline: The NOSTRIL trial"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-0112","authenticated-orcid":false,"given":"Justin P.","family":"McWilliams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4507-3433","authenticated-orcid":false,"given":"Shamaita","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihey","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Seals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Tangchaiburana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R.","family":"Duckwiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1111\/jth.15662_bb0010","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia","volume":"173","author":"Faughnan","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1111\/jth.15662_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4193\/Rhin17.166","article-title":"Intranasal bevacizumab in the treatment of HHT \u2010related epistaxis: a systematic review","volume":"56","author":"Stokes","year":"2018","journal-title":"Rhinology"},{"issue":"3","key":"10.1111\/jth.15662_bb0020","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/lary.21415","article-title":"Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia\u2010associated epistaxis","volume":"121","author":"Karnezis","year":"2011","journal-title":"Laryngoscope"},{"issue":"3","key":"10.1111\/jth.15662_bb0025","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.otc.2016.02.010","article-title":"Treatment of hereditary hemorrhagic telangiectasia\u2013related epistaxis","volume":"49","author":"Sautter","year":"2016","journal-title":"Otolaryngol Clin North Am"},{"issue":"1","key":"10.1111\/jth.15662_bb0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/0194599818797316","article-title":"Medical treatment for epistaxis in hereditary hemorrhagic telangiectasia: a meta\u2010analysis","volume":"160","author":"Hsu","year":"2019","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"3","key":"10.1111\/jth.15662_bb0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/lary.22501","article-title":"Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy","volume":"122","author":"Karnezis","year":"2012","journal-title":"Laryngoscope"},{"issue":"5","key":"10.1111\/jth.15662_bb0040","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/lary.20159","article-title":"The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia","volume":"119","author":"Simonds","year":"2009","journal-title":"Laryngoscope"},{"issue":"4","key":"10.1111\/jth.15662_bb0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5603\/FHC.a2016.0022","article-title":"Doxycycline down\u2010regulates matrix metalloproteinase expression and inhibits NF\u2010\u03baB signaling in LPS\u2010induced PC3 cells","volume":"54","author":"Ogut","year":"2016","journal-title":"Folia Histochem Cytobiol"},{"issue":"4","key":"10.1111\/jth.15662_bb0050","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ejhg.2009.188","article-title":"Hereditary haemorrhagic telangiectasia: from symptomatic management to pathogenesis based treatment","volume":"18","author":"Fern\u00e1ndez\u2010Fern\u00e1ndez","year":"2010","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"10.1111\/jth.15662_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvir.2014.12.306","article-title":"Novel pharmacological therapy for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia","volume":"26","author":"Jordan","year":"2015","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"10.1111\/jth.15662_bb0060","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.thromres.2014.06.012","article-title":"Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid\u2010a double\u2010blind placebo\u2010controlled cross\u2010over phase IIIB study","volume":"134","author":"Geisthoff","year":"2014","journal-title":"Thromb Res"},{"issue":"2","key":"10.1111\/jth.15662_bb0065","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"sup486","key":"10.1111\/jth.15662_bb0070","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/00016489109134996","article-title":"Regeneration of nasal mucosa following mechanical injury","volume":"111","author":"Ohashi","year":"1991","journal-title":"Acta Otolaryngol"},{"issue":"4","key":"10.1111\/jth.15662_bb0075","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF00265856","article-title":"Doxycycline tolerance study","volume":"40","author":"Story","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1111\/jth.15662_bb0080","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4269\/ajtmh.2009.09-0214","article-title":"Sex affects the steady\u2010state pharmacokinetics of primaquine but not doxycycline in healthy subjects","volume":"81","author":"Binh","year":"2009","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"10.1111\/jth.15662_bb0085","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","article-title":"An epistaxis severity score for hereditary hemorrhagic telangiectasia","volume":"120","author":"Hoag","year":"2010","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1111\/jth.15662_bb0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2307\/2530496","article-title":"The crossover experiment for clinical trials","volume":"36","author":"Brown","year":"1980","journal-title":"Biometrics"},{"key":"10.1111\/jth.15662_bb0095","series-title":"Cross\u2010Over Experiments: Design, Analysis and Application","author":"Ratkowsky","year":"1992"},{"key":"10.1111\/jth.15662_bb0100","unstructured":"National Institutes of Health NCI. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. 2017."},{"issue":"10","key":"10.1111\/jth.15662_bb0105","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/14728222.2017.1365839","article-title":"Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia","volume":"21","author":"Ruiz\u2010Llorente","year":"2017","journal-title":"Expert Opin Ther Targets"},{"issue":"9412","key":"10.1111\/jth.15662_bb0110","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0140-6736(04)15732-2","article-title":"A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4)","volume":"363","author":"Gallione","year":"2004","journal-title":"Lancet"},{"issue":"7","key":"10.1111\/jth.15662_bb0115","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ejhg.2009.35","article-title":"Hereditary haemorrhagic telangiectasia: a clinical and scientific review","volume":"17","author":"Govani","year":"2009","journal-title":"Eur J Hum Genet"},{"issue":"8","key":"10.1111\/jth.15662_bb0120","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT\u2010Bleed study","volume":"106","author":"Al\u2010Samkari","year":"2021","journal-title":"Haematologica"},{"key":"10.1111\/jth.15662_bb0125","article-title":"Pazopanib for severe bleeding and transfusion\u2010dependent anemia in hereditary hemorrhagic telangiectasia","author":"Parambil","year":"2021","journal-title":"Angiogenesis"},{"key":"10.1111\/jth.15662_bb0130","unstructured":"McCrae K. Pomalidomide for the treatment of bleeding in HHT (PATH\u2010HHT). The Cleveland Clinic. ClinicalTrials.gov Identifier. NCT03910244."},{"issue":"1","key":"10.1111\/jth.15662_bb0135","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13023-020-01453-1","article-title":"Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding","volume":"15","author":"Beckman","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1111\/jth.15662_bb0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0049-3848(99)00075-4","article-title":"Hereditary hemorrhagic telangiectasia response to aminocaproic acid treatment","volume":"96","author":"Annichino\u2010Bizzacchi","year":"1999","journal-title":"Thromb Res"},{"issue":"12","key":"10.1111\/jth.15662_bb0145","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1056\/NEJM200109203451216","article-title":"Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia","volume":"345","author":"Sabb\u00e0","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1111\/jth.15662_bb0150","article-title":"Tranexamic acid for patients with nasal haemorrhage (epistaxis)","volume":"12","author":"Joseph","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1111\/jth.15662_bb0155","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0001-6519(07)74897-5","article-title":"Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu\u2010Osler\u2010Weber disease) with tranexamic acid","volume":"58","author":"Morales\u2010Angulo","year":"2007","journal-title":"Acta Otorrinolaringol Esp"},{"issue":"1","key":"10.1111\/jth.15662_bb0160","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00277-014-2169-y","article-title":"The use of anti\u2010fibrinolytic agents in patients with HHT: a retrospective survey","volume":"94","author":"Zaffar","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1111\/jth.15662_bb0165","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.thromres.2018.07.004","article-title":"Characteristics and outcomes of venous thromboembolism in patients with hereditary hemorrhagic telangiectasia","volume":"169","author":"Chaturvedi","year":"2018","journal-title":"Thromb Res"},{"issue":"2","key":"10.1111\/jth.15662_bb0170","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1160\/TH06-07-0373","article-title":"Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK\u20101\/endoglin pathway in endothelial cells","volume":"97","author":"Fernandez","year":"2007","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1111\/jth.15662_bb0175","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/jth.12654","article-title":"Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross\u2010over controlled trial in a rare disease","volume":"12","author":"Gaillard","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1111\/jth.15662_bb0180","first-page":"818","article-title":"Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor\u2010beta1 as well as high ALK1 tissue expression","volume":"90","author":"Sadick","year":"2005","journal-title":"Haematologica"},{"issue":"1","key":"10.1111\/jth.15662_bb0185","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1167\/iovs.12-10323","article-title":"Doxycycline\u2010mediated inhibition of corneal angiogenesis: an MMP\u2010independent mechanism","volume":"54","author":"Su","year":"2013","journal-title":"Invest Ophthalmol vis Sci"},{"issue":"6","key":"10.1111\/jth.15662_bb0190","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/neuros\/nyx633","article-title":"The role of matrix metalloproteinase\u20103 in the doxycycline attenuation of intracranial venous hypertension\u2010induced angiogenesis","volume":"83","author":"Zou","year":"2018","journal-title":"Neurosurgery"},{"key":"10.1111\/jth.15662_bb0195","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2939658","article-title":"Doxycycline inhibits IL\u201017\u2010stimulated MMP\u20109 expression by downregulating ERK1\/2 activation: implications in myogenic differentiation","volume":"2016","author":"Obradovi\u0107","year":"2016","journal-title":"Mediators Inflamm"},{"issue":"5","key":"10.1111\/jth.15662_bb0200","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1378\/chest.124.5.2017","article-title":"Pulmonary capillary hemangiomatosis with atypical endotheliomatosis: successful antiangiogenic therapy with doxycycline","volume":"124","author":"Ginns","year":"2003","journal-title":"Chest"},{"key":"10.1111\/jth.15662_bb0205","unstructured":"Doxycycline for Hereditary Hemorrhagic Telangiectasia (HHT). Unity Health Toronto. ClinicalTrials.gov Identifier: NCT03397004."},{"key":"10.1111\/jth.15662_bb0210","article-title":"Safety and efficacy review of doxycycline","volume":"1","author":"Holmes","year":"2009","journal-title":"Clin Med Ther"},{"issue":"4","key":"10.1111\/jth.15662_bb0215","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/archderm.139.4.459","article-title":"Effects of subantimicrobial\u2010dose doxycycline in the treatment of moderate acne","volume":"139","author":"Skidmore","year":"2003","journal-title":"Arch Dermatol"},{"issue":"10","key":"10.1111\/jth.15662_bb0220","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/jac\/dky174","article-title":"Life\u2010long antimicrobial therapy: where is the evidence?","volume":"73","author":"Lau","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1111\/jth.15662_bb0225","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40264-019-00806-5","article-title":"Drug\u2010induced photosensitivity\u2014an update: culprit drugs. Prevention and management","volume":"42","author":"Blakely","year":"2019","journal-title":"Drug Saf"},{"issue":"2","key":"10.1111\/jth.15662_bb0230","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1442-2050.2004.00384.x","article-title":"Doxycycline\u2010induced pill esophagitis","volume":"17","author":"Kadayifci","year":"2004","journal-title":"Dis Esophagus"},{"issue":"4","key":"10.1111\/jth.15662_bb0235","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/his.14177","article-title":"Doxycycline\u2010induced spongiotic oesophagitis is associated with eosinophilic vascular degeneration","volume":"77","author":"Medlicott","year":"2020","journal-title":"Histopathology"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15662","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15662","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622001568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622001568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:34:07Z","timestamp":1761536047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622001568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1538783622001568"],"URL":"https:\/\/doi.org\/10.1111\/jth.15662","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"North American Study for the Treatment of Recurrent Epistaxis with Doxycycline: The NOSTRIL trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15662","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}